This week, the FDA granted priority review status to J&J’s JNJ application seeking approval of key pipeline candidate ...

Phase 2 clinical study of firicabtagene autoleucel (firi-cel); Interim analysis results expected to be reported in 1H'25 - - IND application for CRG-023 ...

Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced its five-year growth ...

SHOPPING: Huda Beauty is back with another shade of its bestselling Easy Bake Powder, Ube Birthday Cake, and this may be its ...

The prosecutor-led program continues her look into juvenile justice. It also continues a state-wide examination of the impact ...

Rule could make more medications available over the counter through a process called Additional Condition of Non-prescription Use (ACNU).

Mural nominated two new development candidates, MURA-8518 a novel binding protein-resistant IL-18 with half-life extension, ...

Catalyst Pharmaceuticals settles patent litigation with Teva, delaying generic Firdapse launch until 2035. Legal actions against other defendants remain ongoing.

The Phase III trial successfully saw patients achieving clinical remission and stopping rectal bleeding within 28 days.